Compare FCBC & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FCBC | PSNL |
|---|---|---|
| Founded | 1874 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 810.9M | 729.1M |
| IPO Year | 1996 | 2019 |
| Metric | FCBC | PSNL |
|---|---|---|
| Price | $43.14 | $5.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.20 |
| AVG Volume (30 Days) | 61.3K | ★ 1.7M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 5.26% | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ 2.65 | N/A |
| Revenue | N/A | ★ $69,648,000.00 |
| Revenue This Year | $12.28 | $15.34 |
| Revenue Next Year | $2.55 | $41.46 |
| P/E Ratio | $16.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $31.21 | $3.84 |
| 52 Week High | $44.36 | $11.50 |
| Indicator | FCBC | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 40.10 |
| Support Level | $42.14 | $4.65 |
| Resistance Level | $44.15 | $6.99 |
| Average True Range (ATR) | 0.98 | 0.43 |
| MACD | -0.10 | -0.04 |
| Stochastic Oscillator | 49.79 | 34.29 |
First Community Bankshares Inc is a financial holding company that provides commercial banking products and services. The company is engaged in providing demand deposit accounts, savings, and money market accounts, certificates of deposits; commercial, consumer, and real estate mortgage loans, and lines of credit; various credit card, debit card, and automated teller machine card services; corporate and personal trust services; investment management services and life, health, and property and casualty insurance products. The company's revenue is mainly derived from interest, fees, and commissions.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.